PACB Files 8-K on Financial Condition, NASDAQ Listing Confirmed

TL;DR

**PACB filed an 8-K, confirming its NASDAQ listing and regulatory compliance.**

AI Summary

Pacific Biosciences of California, Inc. (PACB) filed an 8-K on January 8, 2024, to report on its financial condition and other events. This filing indicates that the company's common stock, with a par value of $0.001 per share, is registered on The NASDAQ Stock Market LLC under the trading symbol PACB. This matters to investors because it confirms the company's continued compliance with SEC regulations and its listing on a major stock exchange, providing transparency and liquidity for shareholders.

Why It Matters

This filing confirms Pacific Biosciences' ongoing compliance with SEC regulations and its listing on NASDAQ, which is crucial for investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This 8-K filing is routine and primarily confirms existing information, posing minimal new risk to investors.

Analyst Insight

Investors should note this routine filing confirms PACB's continued regulatory compliance and NASDAQ listing, which are foundational for trading. No immediate action is suggested by this specific filing, but it serves as a baseline for future financial disclosures.

Key Numbers

• $0.001 — Par value per share (The par value of Pacific Biosciences' common stock.)
• 001-34899 — Commission File Number (The SEC file number for Pacific Biosciences.)

Key Players & Entities

• PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — the registrant filing the 8-K
• The NASDAQ Stock Market LLC (company) — the exchange where PACB common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock
• January 8, 2024 (date) — date of earliest event reported and filing date

FAQ

From the Filing

0001299130-24-000005.txt : 20240108 0001299130-24-000005.hdr.sgml : 20240108 20240108080320 ACCESSION NUMBER: 0001299130-24-000005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 24518421 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20240108.htm 8-K pacb-20240108 0001299130 false 0001299130 2024-01-08 2024-01-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2024 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 8, 2024, Pacific Biosciences of California, Inc. (the “Company”) issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter and year ended December 31, 2023 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed “filed” for purposes of S